Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing

seekingalpha2021-10-08

Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine. Per the...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Stripey
2021-10-09
Stripey
Will the demand still be around by the time they start selling?
Winalot
2021-10-08
Winalot
Come come come. More good news please
- vic78:
  👍👍
bigninja
2021-10-08
bigninja
Gasp. So many vax
LimHianYew
2021-10-08
LimHianYew
Good news

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1198728824?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-08 21:20","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1198728824","market":"us","top_or_hot":-1,"title":"Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing","media":"seekingalpha","content":"<div>\n<p>Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.\n\nPer the...</p>\n\n<a href=\"https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-08 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.\n\nPer the...</p>\n\n<a href=\"https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing","article_id":"1198728824","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198728824","pubTimestamp":1633699239,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"诺瓦瓦克斯医药与马比昂达成3.72亿美元的新冠肺炎疫苗制造协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.\n\nPer the terms, Mabion is expected to produce a COVID-19 vaccine candidate antigen under the name NVX-CoV2373 beginning Dec. 2021 in compliance with the GMP standard. The commercial manufacturing agreement will run from 2022 to 2025 with an option for extension.\nPreviously, Novavax(NASDAQ:NVAX)delayed the production and regulatory timeline for its protein-based vaccine candidate named NVX-CoV2373.\nHowever, it has generated promising results in a large Phase 3 clinical trial indicating 100% protection against moderate and severe COVID-19 with ~90% overall efficacy.\nNovavax (NVAX) shares surged in September when the company announced the regulatory submission to the World Health Organization (WHO) seeking an emergency use listing (EUL) for the vaccine candidate.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":821261140,"gmtCreate":1633748502632,"gmtModify":1633748502736,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Will the demand still be around by the time they start selling?","listText":"Will the demand still be around by the time they start selling?","text":"Will the demand still be around by the time they start selling?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821261140","repostId":1198728824,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":821345744,"gmtCreate":1633701945854,"gmtModify":1633701945967,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Come come come. More good news please","listText":"Come come come. More good news please","text":"Come come come. More good news please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/821345744","repostId":1198728824,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6136414,"gmtCreate":1633733407287,"gmtModify":1634718355807,"authorId":3584874174562489,"author":{"id":3584874174562489,"authorId":3584874174562489,"name":"vic78","avatar":"https://static.tigerbbs.com/d4dc3bd30cec435b0345175f72eeb4dc","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":821345744,"type":1,"supId":0,"prevId":0,"content":"👍👍","text":"👍👍","html":"👍👍"}],"langContent":"CN"},{"id":821345660,"gmtCreate":1633701915235,"gmtModify":1633701930479,"author":{"id":"3580706487697247","authorId":"3580706487697247","name":"bigninja","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Gasp. So many vax","listText":"Gasp. So many vax","text":"Gasp. So many vax","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821345660","repostId":1198728824,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":821365081,"gmtCreate":1633700068184,"gmtModify":1633700068797,"author":{"id":"3576363559636103","authorId":"3576363559636103","name":"LimHianYew","avatar":"https://static.tigerbbs.com/6d37a520eb4e35950b060938ddb5e317","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821365081","repostId":1198728824,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":83,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198728824"}